Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adenocarcinoma of the pancreas~* no prior chemo except adjuvant~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1~* peripheral neuropathy \</= Gr. 1~Exclusion Criteria:~* Pregnant/lactating females~* Uncontrolled heart disease, diabetes, psychiatric disorder~* Therapeutic doses of Warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capecitabine, docetaxel, gemcitabine (Type: EXPERIMENTAL): Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.

Based on this trial design, predict the completion outcome and termination type (if applicable).